Tango Therapeutics, Inc. (TNGX)
After hours:
| Previous Close | 7.70 |
| Open | 7.51 |
| Bid | 7.23 x 100 |
| Ask | 7.30 x 400 |
| Day's Range | 7.20 - 7.80 |
| 52 Week Range | 2.47 - 13.03 |
| Volume | |
| Avg. Volume | 616,086 |
| Market Cap | 777.031M |
| Beta (5Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.08 |
| Earnings Date | May 07, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.57 |
Business WireTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 01, 2024--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective April 1, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 139,453 shares of its common stock and 23,698 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan
GuruFocus.comTango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial Results
Advancements in Oncology Pipeline and Strong Cash Position Highlighted
Business WireTango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
BOSTON, March 18, 2024--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.
